Sign up to save your podcasts
Or
Share Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
CME credits: 0.50
Valid until: 02-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/crossing-boundaries-cetp-inhibitors-and-the-next-frontier-in-lipid-control/33025/
Cardiologists explore advances in lipid management, from statin intolerance to emerging lipid targets like ApoB and non-HDL cholesterol. The series emphasizes the pivotal role of combination therapy—including ezetimibe, PCSK9 inhibitors, and novel agents such as bempedoic acid and inclisiran—in achieving LDL-C goals. Special focus is given to cholesteryl ester transfer protein (CETP) inhibition as a breakthrough strategy, with trials showing potent LDL-C reduction, improved goal attainment, and promising effects on cognition and inflammation. Together, these discussions highlight how CETP inhibitors may redefine future cardiovascular therapy.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.50
Valid until: 02-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/crossing-boundaries-cetp-inhibitors-and-the-next-frontier-in-lipid-control/33025/
Cardiologists explore advances in lipid management, from statin intolerance to emerging lipid targets like ApoB and non-HDL cholesterol. The series emphasizes the pivotal role of combination therapy—including ezetimibe, PCSK9 inhibitors, and novel agents such as bempedoic acid and inclisiran—in achieving LDL-C goals. Special focus is given to cholesteryl ester transfer protein (CETP) inhibition as a breakthrough strategy, with trials showing potent LDL-C reduction, improved goal attainment, and promising effects on cognition and inflammation. Together, these discussions highlight how CETP inhibitors may redefine future cardiovascular therapy.
=